» Articles » PMID: 26903652

ER Stress Stimulates Production of the Key Antimicrobial Peptide, Cathelicidin, by Forming a Previously Unidentified Intracellular S1P Signaling Complex

Overview
Specialty Science
Date 2016 Feb 24
PMID 26903652
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

We recently identified a previously unidentified sphingosine-1-phosphate (S1P) signaling mechanism that stimulates production of a key innate immune element, cathelicidin antimicrobial peptide (CAMP), in mammalian cells exposed to external perturbations, such as UVB irradiation and other oxidative stressors that provoke subapoptotic levels of endoplasmic reticulum (ER) stress, independent of the well-known vitamin D receptor-dependent mechanism. ER stress increases cellular ceramide and one of its distal metabolites, S1P, which activates NF-κB followed by C/EBPα activation, leading to CAMP production, but in a S1P receptor-independent fashion. We now show that S1P activates NF-κB through formation of a previously unidentified signaling complex, consisting of S1P, TRAF2, and RIP1 that further associates with three stress-responsive proteins; i.e., heat shock proteins (GRP94 and HSP90α) and IRE1α. S1P specifically interacts with the N-terminal domain of heat shock proteins. Because this ER stress-initiated mechanism is operative in both epithelial cells and macrophages, it appears to be a universal, highly conserved response, broadly protective against diverse external perturbations that lead to increased ER stress. Finally, these studies further illuminate how ER stress and S1P orchestrate critical stress-specific signals that regulate production of one protective response by stimulating production of the key innate immune element, CAMP.

Citing Articles

Sphingosine kinase 1 inhibition aggravates vascular smooth muscle cell calcification.

Razazian M, Bahiraii S, Jannat I, Tiffner A, Beilhack G, Levkau B Pflugers Arch. 2025; .

PMID: 39899071 DOI: 10.1007/s00424-025-03068-6.


Role of Sphingosine-1-Phosphate Signaling Pathway in Pancreatic Diseases.

Fu F, Li W, Zheng X, Wu Y, Du D, Han C Int J Mol Sci. 2024; 25(21).

PMID: 39519028 PMC: 11545938. DOI: 10.3390/ijms252111474.


Contribution of Keratinocytes in Skin Cancer Initiation and Progression.

Dainese-Marque O, Garcia V, Andrieu-Abadie N, Riond J Int J Mol Sci. 2024; 25(16).

PMID: 39201498 PMC: 11354502. DOI: 10.3390/ijms25168813.


Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.

Sukocheva O, Neganova M, Aleksandrova Y, Burcher J, Chugunova E, Fan R Cell Commun Signal. 2024; 22(1):251.

PMID: 38698424 PMC: 11064425. DOI: 10.1186/s12964-024-01626-6.


Sphingosine-1-Phosphate Inhibition Increases Endoplasmic Reticulum Stress to Enhance Oxaliplatin Sensitivity in Pancreatic Cancer.

Gao Z, Janakiraman H, Xiao Y, Kang S, Dong J, Choi J World J Oncol. 2024; 15(2):169-180.

PMID: 38545484 PMC: 10965266. DOI: 10.14740/wjon1768.


References
1.
Pasupuleti M, Schmidtchen A, Malmsten M . Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol. 2011; 32(2):143-71. DOI: 10.3109/07388551.2011.594423. View

2.
Inesi G, Wade R, Rogers T . The sarcoplasmic reticulum Ca2+ pump: inhibition by thapsigargin and enhancement by adenovirus-mediated gene transfer. Ann N Y Acad Sci. 1999; 853:195-206. DOI: 10.1111/j.1749-6632.1998.tb08267.x. View

3.
Marcu M, Doyle M, Bertolotti A, Ron D, Hendershot L, Neckers L . Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol. 2002; 22(24):8506-13. PMC: 139892. DOI: 10.1128/MCB.22.24.8506-8513.2002. View

4.
Zuehlke A, Johnson J . Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2009; 93(3):211-7. PMC: 2810645. DOI: 10.1002/bip.21292. View

5.
Song X, Zhao Z, Qi X, Tang S, Wang Q, Zhu T . Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90. Oncotarget. 2015; 6(7):5263-74. PMC: 4467147. DOI: 10.18632/oncotarget.3029. View